1. Home
  2. AMPH vs DBVT Comparison

AMPH vs DBVT Comparison

Compare AMPH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$18.72

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.05

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
DBVT
Founded
1996
2002
Country
United States
France
Employees
N/A
90
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
1.1B
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
AMPH
DBVT
Price
$18.72
$19.05
Analyst Decision
Buy
Buy
Analyst Count
8
7
Target Price
$28.38
$32.04
AVG Volume (30 Days)
710.6K
205.9K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
0.14
N/A
Revenue
$719,887,000.00
$5,636,000.00
Revenue This Year
$6.90
$35.04
Revenue Next Year
$4.64
$2,360.78
P/E Ratio
$137.93
N/A
Revenue Growth
N/A
35.77
52 Week Low
$16.65
$7.53
52 Week High
$31.26
$26.19

Technical Indicators

Market Signals
Indicator
AMPH
DBVT
Relative Strength Index (RSI) 44.87 47.09
Support Level $16.84 $18.89
Resistance Level $20.08 $21.61
Average True Range (ATR) 0.80 0.78
MACD 0.11 0.00
Stochastic Oscillator 73.53 38.41

Price Performance

Historical Comparison
AMPH
DBVT

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: